Shifts in patient results due to reagent lot changes are a major issue for laboratories, and their investigation is both time-consuming and expensive. In a recent article, Algeciras-Schimnich et al. (1 ) point out the effect that reagent lot-to-lot changes over time can have on patient results and how these shifts, if large enough, could lead to misdiagnosis and inappropriate treatment. As was the case in this article, on insulin-like growth factor 1, it is often clinicians who alert the laboratory to changes in patient results. We have had similar experiences for a number of analytes, including creatinine. For this analyte, clinicians monitoring renal transplantation patients have asked whether changes as small as from 1.13 mg/dL (100 mol/L) to 1.24 mg/dL (110 mol/L) are real or due to shifts in the assay.
In the laboratory, shifts in patient results can be caused by a number of assay system components, but the most likely are reagent lot changes, as described by Algeciras-Schimnich et al. (1 ) , or variations in the assigned values for calibrators (2 ) . In accordance with European Union Directive 98/79/ EC, manufacturers should assign values for calibrators via a welldefined traceability chain, but as described recently, there are no agreed criteria for defining allowable limits for the individual steps of the chain (3 ).
Laboratories experience additional complications with lot changes, because some manufacturers assign values for QC material to specific reagent and/or calibration lots, e.g., Roche Precipath and Precinorm, which can mask any shifts in patient results. Furthermore, we have observed, especially for alkaline phosphatase, shifts in third-party QC material with reagent lot changes that on investigation led to no shift in patient results. For some analytes, monitoring external quality assurance may not always show lot-to-lot shifts to have occurred in the laboratory when one manufacturer's method dominates the market. The median target value for these analytes will be highly influenced by the predominant method, and its value is likely to be the median value for the lot in use. As Algeciras-Schimnich et al. (1 ) pointed out, it is not practical for every laboratory to do a full evaluation of every lot change, whether reagent or calibrator change. They also question whether manufacturers' criteria are sufficiently stringent. We suggest that currently they probably are not, despite the regulatory requirements (2 ). Even for albumin, a very commonly measured analyte with a welldocumented methodology, the reference measurement system (and the associated uncertainty) is probably not adequate to guarantee the accuracy required for the clinical usefulness of this analyte (4 ) .
One suggestion to address the problem is to enable centralized monitoring of patient results with coordination by the manufacturer, especially for low-volume tests. That would require agreement for laboratories to release their deidentified results. This approach may happen eventually, but in the meantime, laboratories must develop procedures to recognize and evaluate lot-to-lot changes. Monitoring the mean of the healthy population also provides a means of assessing lot-related changes, but such monitoring is by its very nature a retrospective assessment.
It is not that laboratories are seeing more variation in different lots, but as assays and equipment become more precise and clinicians become more demanding, laboratories are tightening their acceptability criteria. With personalized medicine and wellness testing becoming more prevalent, laboratories and manufacturers will need to work together to ensure that the results they produce are both accurate and meaningful. Whichever way the problem is tackled in the future, lot-to-lot changes are going to be a major issue confronting all laboratories. Our initial results with LCGreenPlus suggested that the T m was primarily a function of the PCR yield rather than the allele sequence. This was tested by subjecting a glpF allele 321 sample to PCR in LCGreenPlus master mix, making a dilution series of the reaction products in the same master mix, and then subjecting the dilutions to HRMA. As predicted, the T m values in both melting domains were inversely correlated with DNA concentration (Fig. 1) .
We reasoned that the inverse correlation between T m and DNA concentrationindicatedchangestothe affinity between the DNA strands, and so perturbing the system with an agent that changes the affinity between strands might provide mechanistic insight. Mg 2ϩ concentration impacts strand binding and correlates with T m in the low millimole-perliter range (5 ). After the PCR reactions and before the HRM assays, we increased the MgCl 2 concentration from 2 mmol/L (unmodified master mix) to 6 mmol/L. This completely eliminated the LCGreenPlusdependent inverse correlation between DNA concentration and T m (Fig. 1) . Similar results were obtained with 5 mmol/L MgCl 2 ; however, at 3 mmol/L MgCl 2 the inverse correlation remained.
We tested HRMA in the presence of 6 mmol/L MgCl 2 to resolve the glpF alleles. This was done by adding MgCl 2 either before or after the PCR. In both experiments, the 4 alleles were resolved into 3 distinct melt curves that corresponded to the 3 different %GϩC contents of the alleles. When MgCl 2 was added before the PCR there was substantial PCR yield variation, suggesting that 6 mmol/L MgCl 2 was not optimal for this PCR. Nevertheless, allele discrimination was identical as to when the MgCl 2 concentration was increased to 6 mmol/L post-PCR.
Other PCR amplimers of sizes 186 bp and 83 bp were tested. The 186-bp fragment gave essentially identical results as the glpF fragment used initially. The 83-bp fragment provided similar results except at the very lowest DNA concentrations, close to detection limit for the Rotorgene device. Then, the inverse correlation between T m and DNA concentration at 3 mmol/L MgCl 2 was not evident, and a direct correlation between T m and DNA concentration was observed in the presence of 6 mmol/L MgCl 2 .
We have formulated a model to explain these observations. It is known that intercalation of LCGreenPlus into double-stranded DNA increases T m . The only relevant parameter that changes in accordance with DNA concentrationinthepresenceofaconstant concentration of LCGreenPlus is the DNA/LCGreenPlus stoichiometry. This will modulate the saturation state (and consequent T m ) of the DNA if the LCGreenPlus concentration is comparable to the concentration of LCGreenPlus binding sites. Therefore, we postulate that changes in T m are consequent to changes in this stoichiometry. Raising the MgCl 2 to 6
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